MNCs Return To India With Big Bang; Some Call It Their Waterloo, Others Say Time To Grow Strong

MUMBAI - As financial analysts settle down after a hectic weekend of hair-splitting number crunching over the $3.72 billion Abbott-Piramal deal, a few experts are calling it the great return of the multinational pharmaceutical companies in India, juxtaposing the latest advent with their sudden exits in the '70s